Targeting HIV-1 Where It Hurts

Targeting HIV-1 Where It Hurts

Show other versions (1)

Bibliographic Details
Main Authors:	Ahmed, T, Hayes, P, Borthwick, N, Ondondo, B, Hayton, E, Colloca, S, Nicosia, A, McMichael, A, Gilmour, J, Dorrell, L, Hanke, T
Format:	Conference item
Published:	2013

Similar Items

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Where Does It Hurt?
by: Addyson Frattura
Published: (2022-12-01)

Hitting Where It Hurts: Absurdity as an Artistic Method
by: Gabriele Jutz
Published: (2021-12-01)

P17-05. Dealing with HIV-1 diversity
by: Rosario, M, et al.
Published: (2009)

The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics
by: Ondondo, B, et al.
Published: (2014)

HIV-1 conserved mosaics delivered by regimens with integration-deficient, DC-targeting lentiviral vector induce robust T cells
by: Hanke, T, et al.
Published: (2016)

Dealing with HIV-I diversity
by: Rosario, M, et al.
Published: (2009)

Therapeutic immunization for the control of HIV-1: where are we now?
by: Dorrell, L
Published: (2006)

Therapeutic immunization for the control of HIV-1: where are we now?
by: Dorrell, L
Published: (2006)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
by: Rosario, M, et al.
Published: (2012)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
by: Rosario, M, et al.
Published: (2012)

Detection of broad functional gag-specific CD4+T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Ondondo, B, et al.
Published: (2006)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
by: Ondondo, B, et al.
Published: (2006)

The immune response to HIV
by: McMichael, A, et al.
Published: (2009)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.
by: Borthwick, N, et al.
Published: (2014)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
by: Hanke, T, et al.
Published: (2008)

Where is God when it hurts? Theodicy from the pain of COVID-19
by: Kelebogile T. Resane
Published: (2023-03-01)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
by: Dorrell, L, et al.
Published: (2006)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

Comment on clinical development of candidate HIV vaccines: different problems for different vaccines.
by: McMichael, A, et al.
Published: (2014)

Home Is Where the Hurt Is: Trauma, Alienation, and Identity in Kate O’Riordan’s The Boy in the Moon
by: Jennifer A. Slivka
Published: (2019-10-01)

Is it my body, that hurts? Is it my soul, that hurts? In any case – it hurts!
by: Sanja Temnik, et al.
Published: (2009-07-01)

HIV-1: from escapism to conservatism.
by: Hanke, T, et al.
Published: (2011)

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
by: Ondondo, B, et al.
Published: (2014)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Rowland-Jones Sarah L, et al.
Published: (2006-12-01)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
by: Yang, H, et al.
Published: (2007)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
by: Ondondo, B, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
by: Ondondo, B, et al.
Published: (2013)